Fibrin clot strength is associated with increased risk of major adverse cardiac events after TAVR

Patients after transcatheter aortic valve replacement (TAVR) are at increased risk of both major adverse cardiac events (MACE), including ischemic and thrombotic complications, as well as significant bleeding. Given this delicate balance between prothrombotic and hemorrhagic risk, the assessment of...

Full description

Saved in:
Bibliographic Details
Main Authors: Hesselbarth, David (Author) , D’Orazio, Michelle (Author) , Ciccarone, Giovanni (Author) , Gjermeni, Diona (Author) , Jülch, Carina (Author) , Wessinger, Marius (Author) , Maslarska, Mariya (Author) , Rilinger, Jonathan (Author) , Hilgendorf, Ingo (Author) , Wolf, Dennis (Author) , Kaier, Klaus (Author) , Dürschmied, Daniel (Author) , Pottgiesser, Torben (Author) , von zur Mühlen, Constantin (Author) , Westermann, Dirk (Author) , Olivier, Christoph B. (Author)
Format: Article (Journal)
Language:English
Published: November 2025
In: Clinical research in cardiology
Year: 2025, Volume: 114, Issue: 11, Pages: 1606-1615
ISSN:1861-0692
DOI:10.1007/s00392-025-02749-7
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00392-025-02749-7
Get full text
Author Notes:David Hesselbarth, Michelle D’Orazio, Giovanni Ciccarone, Diona Gjermeni, Carina Jülch, Marius Wessinger, Mariya Maslarska, Jonathan Rilinger, Ingo Hilgendorf, Dennis Wolf, Klaus Kaier, Daniel Duerschmied, Torben Pottgiesser, Constantin von zur Mühlen, Dirk Westermann, Christoph B. Olivier
Description
Summary:Patients after transcatheter aortic valve replacement (TAVR) are at increased risk of both major adverse cardiac events (MACE), including ischemic and thrombotic complications, as well as significant bleeding. Given this delicate balance between prothrombotic and hemorrhagic risk, the assessment of hemostatic markers might help identify patients at increased risk.
Item Description:Online veröffentlicht: 6. Oktober 2025
Gesehen am 04.12.2025
Physical Description:Online Resource
ISSN:1861-0692
DOI:10.1007/s00392-025-02749-7